The custom antibody market is set to witness a CAGR of ~10% during the forecast period. The market growth is primarily driven by expanding R&D activities, increasing demand for customized antibodies, growing adoption of targeted therapeutics, and advancements in antibody engineering and production technologies. However, the high costs associated with development and the time-intensive nature of antibody generation present challenges that may slow market adoption.
Custom antibodies are indispensable tools used by researchers and clinicians in life science research, medicine and diagnostics. These antibodies are designed in laboratories to identify and target a specific antigen of interest with high accuracy and precision that may not be addressed by commercially available antibodies. Antigen synthesis, serum collection, animal immunization (usually in rabbits, mice, or goats), and purification are some of the procedures which are used to produce custom antibodies.
Download a free sample report now 👉
https://meditechinsights.com/custom-antibody-market/request-sample/
Targeted therapeutics drive growth in the custom antibody market
The key factor propelling the custom antibody market growth is the increasing demand for precision medicine and targeted therapeutics. With the growing number of R&D activities and better understanding of the molecular basis of complex diseases like cancer, autoimmune disorders, and infectious diseases, researchers need highly specific antibodies to identify and manipulate disease-related proteins. For instance, in June 2025, BioNTech and Bristol Myers Squibb signed a global collaboration to co-develop and co-commercialize BNT327, BioNTech’s PD L1 × VEGF A next-generation bispecific antibody for multiple solid tumor types.
Custom antibodies have a specific ability to bind precisely to unique epitopes, which can improve the detection in diagnostics and enhance efficacy in therapeutic applications. Additionally, biotech and pharma companies are investing more in custom antibody production to support the development of ADCs (antibody-drug conjugates) and other advanced biologics. For example, in December 2022, Merck announced an exclusive license and collaboration agreement with Kelun-Biotech to co-develop seven investigational preclinical antibody-drug conjugates (ADCs) for cancer treatment. This trend not only fuels market demand but also expands the applications of custom antibodies.
Technological innovations and collaborations boost custom antibody efficiency
In the evolving landscape of biotechnology, custom antibodies have emerged as an invaluable tool, propelling technological advancements in the diagnostic and therapeutic areas. One such notable innovation is the use of custom antibodies in phage display technology. This method allows scientists to rapidly screen billions of antibody variants and identify those with optimal binding to a specific target antigen.
Unlike other methods, this method has gained widespread adoption in industry and academic research, as it enhances the speed, scalability, and ability to produce tailored antibodies, which are significant for therapeutic applications. For instance,
• In December 2024, Antibody Solutions received approval to become a CRO for Levena’s Singularity™ SAPIEN™ Mouse platform, a transgenic animal model which allows researchers to generate high-affinity, human-derived antibodies more efficiently for both therapeutic and diagnostic applications
• In March 2024, Sino Biological, Inc. announced a collaboration with Rapid Novor, Inc. Under this agreement, Sino Biological leveraged Rapid Novors' REmAb monoclonal antibody (mAb) sequencing platform alongside its custom antibody development and production services, providing a seamless pipeline from antibody discovery to delivery
The increasing collaborations among biotech companies and research organizations has improve antibody performance and making the development process more efficient and reproducible. With the growing number of technological innovations, the barrier to entry for high-quality custom antibody production is being lowered, making it more accessible for a broader range of users in the research and diagnostics field.
Competitive Landscape Analysis
The global custom antibody market is marked by the presence of established and emerging market players such as Thermo Fisher Scientific Inc.; Abcam plc; Bio-Rad Laboratories, Inc; Creative Biolabs; Merck KGaA; Agilent Technologies Inc; GenScript; Laboratory Corporation of America; Danaher Corporation; Kaneka Eurogentec S.A.; Bio-Techne; and Sino Biological, Inc., among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Download a sample report for in-depth competitive insights
https://meditechinsights.com/custom-antibody-market/request-sample/
Global Custom Antibody Market Segmentation
This report by Medi-Tech Insights provides the size of the global custom antibody market at the regional- and country-level from 2023 to 2030. The report further segments the market based on type, service, source, application, and end-user.
Market Size & Forecast (2023-2030), By Type, USD Million
• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies
• Others
Market Size & Forecast (2023-2030), By Service, USD Million
• Antibody Development
• Antibody Production & Purification
• Antibody Fragmentation & Labelling
Market Size & Forecast (2023-2030), By Source, USD Million
• Mice
• Rabbit
• Others
Market Size & Forecast (2023-2030), By Application, USD Million
• Oncology
• Infectious Diseases
• Neurology
• Stem cells
• Immunology
• Cardiovascular Diseases
• Others
Market Size & Forecast (2023-2030), By End-user, USD Million
• Hospitals & Clinics
• Academic & Research Institutes
• CRO
• Others
Market Size & Forecast (2023-2030), By Region, USD Million
• North America
o US
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o Rest of Asia Pacific
• Latin America
• Middle East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
[email protected]
Top comments (0)